New combo therapy shows promise in advanced breast cancer trial
NCT ID NCT05501769
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 27 times
Summary
This early-phase trial tested a new combination of two drugs, ARV-471 and everolimus, in 32 people with a certain type of advanced breast cancer (ER+/HER2-). The main goals were to find the safest dose and check for side effects. The study is now complete, and results will help guide future research on this treatment approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Trial Site
San Diego, California, 92037, United States
-
Clinical Trial Site
Santa Monica, California, 90404, United States
-
Clinical Trial Site
Washington D.C., District of Columbia, 20007, United States
-
Clinical Trial Site
Lake Mary, Florida, 32746, United States
-
Clinical Trial Site
Ann Arbor, Michigan, 48109, United States
-
Clinical Trial Site
Nashville, Tennessee, 37203, United States
-
Clinical Trial Site
Barcelona, 08028, Spain
-
Clinical Trial Site
Madrid, 28034, Spain
-
Clinical Trial Site
Valencia, 46018, Spain
Conditions
Explore the condition pages connected to this study.